Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
April 25, 2024 08:00 ET
|
Cerevance
Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others Proceeds will advance Cerevance’s first-in-class...
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
April 22, 2024 08:30 ET
|
Cerevance
BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed...
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 17, 2024 08:30 ET
|
Cerevance
BOSTON, April 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to deliver an oral...
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
April 02, 2024 08:30 ET
|
Cerevance
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
March 13, 2024 08:30 ET
|
Cerevance
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a...
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 27, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a...
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
February 22, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
February 15, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing...
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
December 05, 2023 08:30 ET
|
Cerevance
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced that chief executive...
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
November 28, 2023 08:30 ET
|
Cerevance
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at...